Landmark trial ONTARGET® proves telmisartan is as protective as ramipril and better tolerated in a broad high-risk cardiovascula
0 담기
54 조회 ㆍ 9년 전 업로드 #MICARDIS  #ARB  #cardiovascular  #

Results of 25,620 patient study ONTARGET® (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) presented today at the 57th Annual Scientific Session of the American College ...